Biochemie Gesellschaft M.b.h

Sandoz Ag

Sandoz Gmbh

Biochemie Gesellschaft

Biochemie Gmbh

Biochemie S.a.

Elanco Tiergesundheit Ag

Johannes Ludescher

Hubert Sturm

Siegfried Wolf

Josef Wieser

Gerd Ascher

Peter Kremminger

Ingolf Macher

Werner Veit

Jose Diago

Klaus Totschnig

Mahendra R Patel

Andreas Hotter

Bernhard C Prager

Anup Kumar Ray

Victor Centellas

Martin Decristoforo

Rafael Garcia

Julia Greil

Ulrich Griesser

Johannes Hildebrandt

José Diago

Michael Schranz

Hiren Kumar V Patel

Benjamin Gerlach

Mariappan Anbazhagan

Herbert Sturm

Harald Summer

Rainer Pucher

Werner Heilmayer

Arthur Pichler

Christoph Langes

Hiren V Patel

Andreas Berger

Katharina Reichenbächer

Christian Welz

Jos&eacute; Diago

Gerhard Laus

Immaculada Bosch

Herwig Jennewein

Jordi Rifa

Joan Cabre

Asuncion Esteve

Robert Ziegert-Knepper

Marta Poch

Frtiz Blatter

Herbert Schleich

Ludwig Miller

Robert Ziegert

Gottfried Stubauer

Andreas Schmarda

Mairi Haddow

Katja Vorndran

Oriol Martorell

Albert Codony

Robert E Ziegert-Knepper

A crystalline sodium salt of a compound of formula I (INN: Raltegravir) or a hydrate/solvate thereof is disclosed as well as a process for obtaining the same.

Crystalline sodium salt of an HIV integrase inhibitor

Provided are a crystalline dihydrate of Rivaroxaban, processes for the preparation thereof, pharmaceutical compositions containing the crystalline dihydrate and processes for preparing and storing the pharmaceutical compositions. Also provided are a crystalline formic acid solvate of Rivaroxaban, processes for the preparation of crystalline Rivaroxaban formic acid solvate and the use of the Rivaroxaban formic acid solvate in the manufacture of the crystalline dihydrate of Rivaroxaban.

Crystalline form of rivaroxaban dihydrate

The present invention relates to a method for the production of organic compounds, in particular sodium (6R,7R)-7-[(Z)-2-(5-amino-[1,2,4]thiadiazol-3-yl)-2-hydroxyimino-acetylamino]-8-oxo-3-[(E)-(R)-1'-(5-methyl-2-oxo-[1,3]-dioxol-4-ylmethoxycarbonyl)-2-oxo-[1,3&#x2032;]bipyrrolidinyl-3-ylidenemethyl]-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate (ceftobiprole medocaril), and compounds of the general formula (1) and of the general formula (2), the compounds themselves and intermediates in the production according to the invention.

Method for the production of ceftobiprole medocaril

The present invention relates to processes for preparing a polypeptide or pharmaceutically acceptable salt thereof comprising L-tyrosine, L-alanine, L-glutamate, and L-lysine. The polypeptide or pharmaceutically acceptable salt thereof is preferably glatiramer acetate.

Processes for preparing a polypeptide

The present invention relates to an improved process for preparing a polypeptide or pharmaceutically acceptable salt thereof comprising L-tyrosine, L-alanine, L-glutamate, and L-lysine. The polypeptide or pharmaceutically acceptable salt thereof is preferably glatiramer acetate. The process comprises: (a) polymerizing a mixture of N-carboxyanhydride of L-tyrosine, N-carboxyanhydride of L-alanine, N-carboxyanhydride of a protected L-glutamate and N-carboxyanhydride of a protected L-lysine, in a polar aprotic solvent in the presence of an initiator, to form a protected polypeptide; (b) admixing an acid with the protected polypeptide formed in Step (a) and a solvent, to form a product; and (c) admixing a substance selected from the group consisting of an alkali or alkaline earth metal hydroxide, a carbonate, a hydrogencarbonate, and mixtures thereof, with the product formed in Step (b), and a solvent or a mixture of a solvent and water, to form a deprotected polypeptide or a pharmaceutically acceptable salt thereof.

The present invention is directed to a crystalline form of 2-[6-[3(R)-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-ylmethyl]-benzonitrile, a process for the preparation of said crystalline form and the use thereof in the manufacture of a pharmaceutical composition.

Crystalline form of an organic compound

The present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable salt of caspofungin as active ingredient being useful for the prevention and/or treatment of fungal infections. The compositions additionally comprise specific bulking agents and small amounts or no amounts of an additional pH modifier and may be in a liquid or solid form, e.g. may be lyophilized compositions. The compositions show good stability and reduced amounts of sub-visible particulate matter formed in solutions which are reconstituted from the lyophilized product.

Caspofungin formulations

The present invention relates to stable amorphous 3-De[(2,6-dideoxy-3-C-methyl-3-O-methyl-&#x3b1;-L-ribohexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]erythromycin (telithromycin), methods for the preparation thereof, the use of stable amorphous telithromycin in the treatment of bacterial infections and to pharmaceutical compositions comprising stable amorphous telithromycin.

Amorphous telithromycin compound

The present invention relates to acid addition salts of aripiprazole, a process for preparing said acid addition salts and their use to prepare or purify aripiprazole in the form of a free base or in the form of a pharmaceutically acceptable salt.

Salts of aripiprazole

This invention provides processes for preparing cefepime, including crystalline intermediates of Formula V. 

Processes for the preparations of cefepime

The invention provides an Olanzapine pseudopolymoph Form E. The invention provides methods of preparing polymorphic Olanzapine Form E employing rapid crystallization and seeding. The invention provides methods of preparing anhydrous Olanzapine Form I from the Olanzapine Form E by step-wise drying.

Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E

7-[2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)acetamido]-3-vinyl-cephem-4-carboxylic acid of formula (I), in the form of a crystalline salt and use thereof, e.g. in the preparation of pure cefdinir. In another aspect this invention relates to the compound of formula (I) in the form of a salt, optionally in crystalline form, wherein the salt is selected from the group consisting of phosphate, hydrogen phosphate, mesylate, tosylate, sulfate, hydrogen sulfate and sulfamate. 

Cefdinir intermediate

A process for the production of intermediates having a formula IA that can be used for the synthesis of cephalosporins, such as cefepime of formula V. The intermediates of formula IA are produced by desilyation of a compound of formula II wherein R4 is a silyl-protecting group, with a protic solvent to obtain a compound of formula III, and reacting the compound of formula III with an organic base of formula IV wherein R2 and R3 together represent a C4-alkylene group, and with the adjacent nitrogen atom form a saturated 5-membered heterocycle, and R1 represents a methyl group, to obtain the compound of formula 1A.

Process for production of intermediates for use in cefalosporin synthesis

A salt of PACA with an amidine and its use in the production of cefprozil.

Intermediates in cefprozil production

Growing community of inventors

Breitenbach, Austria

Johannes Ludescher